Myricx Bio is an early stage oncology pharmaceutical company. We are developing inhibitors of the oncoprotein Myc, with the ultimate goal of improving the lives of people with cancer.
Myricx Bio is developing small molecule inhibitors of cMyc, a protein that is deregulated in over 70% of all human cancers. The company has strategic partnerships with Australia’s leading integrated cancer centre, the Peter MacCallum Cancer Centre, and Australia’s premier government research organisation, CSIRO.
Myricx Bio is based in Melbourne, Australia and conducts its research and discovery activities through service providers and research collaborators in Europe, UK, USA and Australia.
